Haemonetics Corporation
HAE
$56.66
-$1.80-3.08%
NYSE
| 12/27/2025 | 09/27/2025 | 06/28/2025 | 03/29/2025 | 12/28/2024 | |
|---|---|---|---|---|---|
| Revenue | -4.02% | -2.45% | 0.91% | 3.95% | 8.14% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -4.02% | -2.45% | 0.91% | 3.95% | 8.14% |
| Cost of Revenue | -14.12% | -11.54% | -7.03% | -0.43% | 5.93% |
| Gross Profit | 4.23% | 5.08% | 7.61% | 7.63% | 10.01% |
| SG&A Expenses | -1.08% | -1.21% | -0.76% | 1.38% | 5.94% |
| Depreciation & Amortization | -5.46% | 9.58% | 27.42% | 50.67% | 60.21% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -8.18% | -5.92% | -2.67% | 2.36% | 7.67% |
| Operating Income | 17.44% | 15.63% | 20.97% | 12.57% | 10.62% |
| Income Before Tax | 37.89% | 36.67% | 43.23% | 39.64% | 2.28% |
| Income Tax Expenses | 49.15% | 39.57% | 47.01% | 29.40% | 0.52% |
| Earnings from Continuing Operations | 34.88% | 35.84% | 42.17% | 42.64% | 2.76% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 34.88% | 35.84% | 42.17% | 42.64% | 2.76% |
| EBIT | 17.44% | 15.63% | 20.97% | 12.57% | 10.62% |
| EBITDA | 11.65% | 12.77% | 18.92% | 15.68% | 14.98% |
| EPS Basic | 42.51% | 41.49% | 45.80% | 44.10% | 2.55% |
| Normalized Basic EPS | 15.38% | 6.67% | 6.78% | 9.24% | 7.50% |
| EPS Diluted | 43.25% | 42.27% | 47.02% | 44.92% | 3.25% |
| Normalized Diluted EPS | 16.02% | 7.37% | 7.48% | 9.85% | 8.02% |
| Average Basic Shares Outstanding | -5.53% | -4.04% | -2.33% | -0.74% | 0.21% |
| Average Diluted Shares Outstanding | -6.04% | -4.63% | -2.97% | -1.30% | -0.27% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |